| __timestamp | Celldex Therapeutics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 9335772 |
| Thursday, January 1, 2015 | 4011000 | 999000 |
| Friday, January 1, 2016 | 102026000 | 978000 |
| Sunday, January 1, 2017 | 96171000 | 952000 |
| Monday, January 1, 2018 | 66449000 | 956000 |
| Tuesday, January 1, 2019 | 42672000 | 8122999 |
| Wednesday, January 1, 2020 | 42534000 | 8712000 |
| Friday, January 1, 2021 | 3068000 | 13980000 |
| Saturday, January 1, 2022 | 1400000 | 21135000 |
| Sunday, January 1, 2023 | 3008000 | 10755000 |
Unleashing insights
In the dynamic world of biotechnology, understanding cost structures is crucial for evaluating company performance. This analysis delves into the cost of revenue trends for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc. from 2014 to 2023.
Celldex's cost of revenue has seen significant fluctuations, peaking in 2014 and 2016 with over $100 million, before plummeting to just $1.4 million in 2022. This represents a dramatic 99% decrease, highlighting potential shifts in operational strategy or market conditions.
Conversely, Iovance's cost of revenue has shown a more stable trajectory, with a notable increase from $952,000 in 2017 to over $21 million in 2022, marking a substantial growth of over 2,000%. This suggests a strategic expansion or increased production capacity.
These insights provide a window into the financial strategies of these biotech firms, reflecting broader industry trends and company-specific developments.
Sanofi vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: GSK plc vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Iovance Biotherapeutics, Inc.
Sarepta Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Cytokinetics, Incorporated vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Bausch Health Companies Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Geron Corporation vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Iovance Biotherapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Iovance Biotherapeutics, Inc. or Celldex Therapeutics, Inc.